Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance

Journal of Virology

Volumn 88, Issue 17, 2014, Pages 9504-9513

  Guo, Dongwei ^a   Zhang, Gang ^a   Wysocki, Tadeusz A ^b   Wysocki, Beata J ^b   Gelbard, Harris A ^c   Liu, Xin Ming ^a   McMillan, JoEllyn M ^a   Gendelman, Howard E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; GAG PROTEIN; NANOPARTICLE; OLIGOPEPTIDE; POLOXAMER; PYRIDINE DERIVATIVE;

CELL CULTURE; CONFOCAL MICROSCOPY; DRUG EFFECTS; ENDOSOME; FLUORESCENCE MICROSCOPY; GROWTH, DEVELOPMENT AND AGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; METABOLISM; THEORETICAL MODEL; TRANSPORT AT THE CELLULAR LEVEL; VIRUS CULTURE;

ANTI-RETROVIRAL AGENTS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; ENDOSOMES; HIV CORE PROTEIN P24; HIV-1; HUMANS; MACROPHAGES; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MODELS, THEORETICAL; NANOPARTICLES; OLIGOPEPTIDES; POLOXAMER; PYRIDINES; VIRUS CULTIVATION;

EID: 84916900120     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01557-14     Document Type: Article

References (54)

1. Wainberg MA. 2011. AIDS: drugs that prevent HIV infection. Nature 469:306-307. http://dx.doi.org/10.1038/469306a.
2. Pretorius E, Klinker H, Rosenkranz B. 2011. The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection. Ther. Drug Monit. 33:265-274. http://dx.doi.org/10.1097/FTD.0b013e31821b42d1.
3. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, Kazatchkine M, Sidibe M, Strathdee SA. 2010. Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet 376:551-563. http://dx.doi.org/10.1016/S0140-6736(10)60928-2.
4. Dash P, Gendelman HE, Roy U, Balkundi S, Alnouti Y, Mosley RLM, Gelbard H, McMillan J, Gorantla S, Poluektova L. 2012. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1 infected humanized mice. AIDS 26: 2135-2144. http://dx.doi.org/10.1097/QAD.0b013e328357f5ad.
5. Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, Gendelman HE. 2010. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J. Neuroimmune Pharmacol. 5:592-601. http://dx.doi.org/10.1007/s11481-010-9198-7.
6. Puligujja P, McMillan J, Kendrick L, Li T, Balkundi S, Smith N, Veerubhotla RS, Edagwa BJ, Kabanov AV, Bronich T, Gendelman HE, Liu XM. 2013. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine 9:1263-1273. http://dx.doi.org/10.1016/j.nano.2013.05.003.
7. Wang X, Li J, Wang Y, Cho KJ, Kim G, Gjyrezi A, Koenig L, Giannakakou P, Shin HJ, Tighiouart M, Nie S, Chen ZG, Shin DM. 2009. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano. 3:3165-3174. http://dx.doi.org/10.1021/nn900649v.
8. Kabanov AV, Gendelman HE. 2007. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci. 32:1054-1082. http://dx.doi.org/10.1016/j.progpolymsci.2007.05.014.
9. Kadiu I, Nowacek A, McMillan J, Gendelman HE. 2011. Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine 6:975-994. http://dx.doi.org/10.2217/nnm.11.27.
10. Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, Mosley RL, Ma Z, Graham S, Chaubal M, Werling J, Rabinow B, Dou H, Gendelman HE. 2009. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine 4:903-917. http://dx.doi.org/10.2217/nnm.09.71.
11. Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, Destache CJ. 2006. Nanotechnology: a focus on nanoparticles as a drug delivery system. J. Neuroimmune Pharmacol. 1:340-350. http://dx.doi.org/10.1007/s11481-006-9032-4.
12. Wood R. 2008. Atazanavir: its role in HIV treatment. Expert Rev. Anti Infect. Ther. 6:785-796. http://dx.doi.org/10.1586/14787210.6.6.785.
13. Schwarcz SK, Hsu LC, Vittinghoff E, Katz MH. 2000. Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996. Am. J. Epidemiol. 152:178-185. http://dx.doi.org/10.1093/aje/152.2.178.
14. Arribas JR, Eron J. 2013. Advances in antiretroviral therapy. Curr. Opin. HIV AIDS 8:341-349. http://dx.doi.org/10.1097/COH.0b013e328361fabd.
15. Rowell JF, Stanhope PE, Siliciano RF. 1995. Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J. Immunol. 155:473-488.
16. Raposo G, Moore M, Innes D, Leijendekker R, Leigh-Brown A, Benaroch P, Geuze H. 2002. Human macrophages accumulate HIV-1 particles in MHC II compartments. Traffic 3:718-729. http://dx.doi.org/10.1034/j.1600-0854.2002.31004.x.
17. Pelchen-Matthews A, Kramer B, Marsh M. 2003. Infectious HIV-1 assembles in late endosomes in primary macrophages. J. Cell Biol. 162: 443-455. http://dx.doi.org/10.1083/jcb.200304008.
18. Goncalves E, Bucher J, Ryll A, Niklas J, Mauch K, Klamt S, Rocha M, Saez-Rodriguez J. 2013. Bridging the layers: towards integration of signal transduction, regulation and metabolism into mathematical models. Mol. Biosyst. 9:1576-1583. http://dx.doi.org/10.1039/c3mb25489e.
19. Karr JR, Sanghvi JC, Macklin DN, Gutschow MV, Jacobs JM, Bolival B, Jr, Assad-Garcia N, Glass JI, Covert MW. 2012. A whole-cell computational model predicts phenotype from genotype. Cell 150:389-401. http://dx.doi.org/10.1016/j.cell.2012.05.044.
20. Clark SC. 1989. Interleukin-6. Multiple activities in regulation of the hematopoietic and immune systems. Ann. N. Y. Acad. Sci. 557:438-443.
21. Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, Wahl LA, Lane HC, Fauci AS, Burke DS, Skillman D, Meltzer MS. 1988. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167:1428-1441. http://dx.doi.org/10.1084/jem.167.4.1428.
22. Nowacek AS, Balkundi S, McMillan J, Roy U, Martinez-Skinner A, Mosley RL, Kanmogne G, Kabanov AV, Bronich T, Gendelman HE. 2011. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J. Control Release 150:204-211. http://dx.doi.org/10.1016/j.jconrel.2010.11.019.
23. Liszewski MK, Yu JJ, O'Doherty U. 2009. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods 47:254-260. http://dx.doi.org/10.1016/j.ymeth.2009.01.002.
24. Kumar R, Vandegraaff N, Mundy L, Burrell CJ, Li P. 2002. Evaluation of PCR-based methods for the quantitation of integrated HIV-1 DNA. J. Virol. Methods 105:233-246. http://dx.doi.org/10.1016/S0166-0934(02) 00105-2.
25. Kalter DC, Nakamura M, Turpin JA, Baca LM, Hoover DL, Dieffenbach C, Ralph P, Gendelman HE, Meltzer MS. 1991. Enhanced HIV replication in macrophage colony-stimulating factor-treated monocytes. J. Immunol. 146:298-306.
26. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. 2006. Development of a macrophagebased nanoparticle platform for antiretroviral drug delivery. Blood 108: 2827-2835. http://dx.doi.org/10.1182/blood-2006-03-012534.
27. Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE. 2009. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 183:661-669. http://dx.doi.org/10.4049/jimmunol.0900274.
28. Martin TM, Wysocki BJ, Beyersdorf JP, Wysocki TA, Pannier AK. Integrating mitosis, toxicity, and transgene expression in a telecommunications packet-switched network model of lipoplex-mediated gene delivery. Biotechnol. Bioeng., in press.
29. Hutagalung AH, Novick PJ. 2011. Role of Rab GTPases in membrane traffic and cell physiology. Physiol. Rev. 91:119-149. http://dx.doi.org/10.1152/physrev.00059.2009.
30. Junghanns JU, Muller RH. 2008. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomedicine 3:295-309. http://dx.doi.org/10.2147/IJN.S595.
31. Kumar L, Verma S, Prasad DN, Bhardwaj A, Vaidya B, Jain AK. 25 February 2014. Nanotechnology: a magic bullet for HIV AIDS treatment. Artif. Cells Nanomed. Biotechnol. http://dx.doi.org/10.3109/21691401.2014.883400.
32. Ramana LN, Sharma S, Sethuraman S, Ranga U, Krishnan UM. 2014. Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic systems. Biochim. Biophys. Acta 1840:476-484. http://dx.doi.org/10.1016/j.bbagen.2013.10.002.
33. Rabinow BE. 2004. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3:785-796. http://dx.doi.org/10.1038/nrd1494.
34. Gollapudi K, Galet C, Grogan T, Zhang H, Said JW, Huang J, Elashoff D, Freedland SJ, Rettig M, Aronson WJ. 2013. Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am. J. Cancer Res. 3:523-529.
35. Schulz R, Moll UM. 2014. Targeting the heat shock protein 90: a rational way to inhibit macrophage migration inhibitory factor function in cancer. Curr. Opin. Oncol. 26:108-113. http://dx.doi.org/10.1097/CCO.0000000000000036.
36. Goshima F, Esaki S, Luo C, Kamakura M, Kimura H, Nishiyama Y. 2014. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer. Int. J. Cancer 134:2865-2877. http://dx.doi.org/10.1002/ijc.28631.
37. Gautam N, Roy U, Balkundi S, Puligujja P, Guo D, Smith N, Liu XM, Lamberty B, Morsey B, Fox HS, McMillan J, Gendelman HE, Alnouti Y. 2013. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob. Agents Chemother. 57:3110-3120. http://dx.doi.org/10.1128/AAC.00267-13.
38. Beduneau A, Ma Z, Grotepas CB, Kabanov A, Rabinow BE, Gong N, Mosley RL, Dou H, Boska MD, Gendelman HE. 2009. Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One 4:e4343. http://dx.doi.org/10.1371/journal.pone.0004343.
39. Meltzer MS, Gendelman HE. 1992. Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease. Curr. Top. Microbiol. Immunol. 181:239-263.
40. Meltzer MS, Nakamura M, Hansen BD, Turpin JA, Kalter DC, Gendelman HE. 1990. Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease. AIDS Res. Hum. Retroviruses 6:967-971.
41. Feng Y, Press B, Wandinger-Ness A. 1995. Rab 7: an important regulator of late endocytic membrane traffic. J. Cell Biol. 131:1435-1452. http://dx.doi.org/10.1083/jcb.131.6.1435.
42. Meng B, Lever AM. 2013. Wrapping up the bad news: HIV assembly and release. Retrovirology 10:5. http://dx.doi.org/10.1186/1742-4690-10-5.
43. Bell NM, Lever AM. 2013. HIV Gag polyprotein: processing and early viral particle assembly. Trends Microbiol. 21:136-144. http://dx.doi.org/10.1016/j.tim.2012.11.006.
44. Bell NM, L'Hernault A, Murat P, Richards JE, Lever AM, Balasubramanian S. 2013. Targeting RNA-protein interactions within the human immunodeficiency virus type 1 lifecycle. Biochemistry 52:9269-9274. http://dx.doi.org/10.1021/bi401270d.
45. Benaroch P, Billard E, Gaudin R, Schindler M, Jouve M. 2010. HIV-1 assembly in macrophages. Retrovirology 7:29. http://dx.doi.org/10.1186/1742-4690-7-29.
46. Varthakavi V, Smith RM, Martin KL, Derdowski A, Lapierre LA, Goldenring JR, Spearman P. 2006. The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 7:298-307. http://dx.doi.org/10.1111/j.1600-0854.2005.00380.x.
47. Kumari S, Mg S, Mayor S. 2010. Endocytosis unplugged: multiple ways to enter the cell. Cell Res. 20:256-275. http://dx.doi.org/10.1038/cr.2010.19.
48. McMahon HT, Boucrot E. 2011. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell. Biol. 12:517-533. http://dx.doi.org/10.1038/nrm3151.
49. Jordens I, Marsman M, Kuijl C, Neefjes J. 2005. Rab proteins, connecting transport and vesicle fusion. Traffic 6:1070-1077. http://dx.doi.org/10.1111/j.1600-0854.2005.00336.x.
50. Sonnichsen B, De Renzis S, Nielsen E, Rietdorf J, Zerial M. 2000. Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11. J. Cell Biol. 149:901-914. http://dx.doi.org/10.1083/jcb.149.4.901.
51. Schonteich E, Wilson GM, Burden J, Hopkins CR, Anderson K, Goldenring JR, Prekeris R. 2008. The Rip11/Rab11-FIP5 and kinesin II complex regulates endocytic protein recycling. J. Cell Sci. 121:3824-3833. http://dx.doi.org/10.1242/jcs.032441.
52. Parent A, Hamelin E, Germain P, Parent JL. 2009. Rab11 regulates the recycling of the beta2-adrenergic receptor through a direct interaction. Biochem. J. 418:163-172. http://dx.doi.org/10.1042/BJ20080867.
53. Yamamoto H, Koga H, Katoh Y, Takahashi S, Nakayama K, Shin HW. 2010. Functional cross-talk between Rab14 and Rab4 through a dual effector, RUFY1/Rabip4. Mol. Biol. Cell 21:2746-2755. http://dx.doi.org/10.1091/mbc.E10-01-0074.
54. Zerial M, McBride H. 2001. Rab proteins as membrane organizers. Nat. Rev. Mol. Cell. Biol. 2:107-117. http://dx.doi.org/10.1038/35052055.